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To the Editor:
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Fig. 1. Course of liver enzymes from May 2009 until June 2012. Alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) values are depicted (IU/L). The
light blue shade areas denoted IFX reﬂect the time of inﬂiximab treatment. Additional immunosuppressive therapy is depicted at the bottom: the large arrow represents a
weaning course or low dose prednisolone, HD represents high dose steroid, the AZA arrow azathioprine, the MF arrow mycophenolate mofetil, and the TAC arrow
tacrolimus.
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909We read with interest the reported association between natural
killer (NK) cell phenotype and treatment outcome in chronic
HCV infection [1]. There is growing evidence that NK cell
function and phenotype, in particular NKp46 expression, are
associated with liver inﬂammation, treatment outcome, and
may even impinge upon the ability to mount a robust CD4+
T-cell response during the successful IFN-a based treatment
of HCV [2–6]. However, this remains a complex ﬁeld with
often apparently conﬂicting reports within the literature.
Methodological variations are often cited as a cause of these
discrepancies.
The paper by Oliviero et al. reporting a novel association
between proportions of peripheral blood CD56dimCD16neg NK
cells and sustained virological response (SVR) is potentially extre-
mely exciting. CD16 is a weak FccRIII activating receptor that is
usually described as present on CD56dim, but not CD56bright, NK
cells in the resting state. CD16 is downregulated on cells that
have recently degranulated [7] and both we and the Mondelli
group have recently reported lower expression of CD16 on intra-
hepatic NK cells compared to peripheral blood [5,6]. Oliviero et al.
report that CD16neg cells make up a mean of 25% of CD56dim NK
cells in HCV patients and higher proportions of these cells are
associated with SVR. Furthermore, the proportion of this subset
increases after initiation of IFNa treatment. They speculate that
these NK cells may have come into contact with infected hepato-
cytes and degranulated, resulting in CD16 downregulation before
returning to the peripheral blood.
Using data from a previously described cohort of HCV p
[6], we found 8% of NK cells are CD56dimCD16neg NK cells
3–17%), thus markedly lower than reported by Oliviero an
leagues. We found no association between the proport
CD56dim/bright or CD56dimCD16neg NK cells and treatmen
come (Fig. 1A and B). What might be the basis for these co
ing ﬁndings? We believe a key difference betwee
methodologies is our inclusion of a cell marker to exclud
cells (Aqua Live/Dead, Invitrogen, Paisley, UK). The proc
storing cells in DSMO-based freezing media and liquid ni
is potentially extremely toxic and it is well known that cell
can result in non-speciﬁc and erratic antibody-binding. We
that without a Live/Dead gate, there is an increase in the p
tion of cells appearing as CD56dimCD16neg. Indeed, retrosp
gating for dead cells revealed the majority (mean = 94.9%
within the CD56dimCD16neg gate and formed on averag
(range 5.2–52.1%) of events in this gate (p <0.0001, Fig.
Therefore, it is possible that dead cell contamination co
mises the data and conclusions presented in the study perf
by Oliviero and colleagues.
The role of NK cells in HCV is currently of great intere
majority of data from peripheral blood and intrahepatic N
are likely to be analysed by ﬂow cytometry. We would the
like to recommend the following points for consideration.
cells should be selected and dead cells excluded from an
Representative FACS plots should demonstrate the lymp
gate, alive/dead staining, doublets, and NK gating. CD14
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CD19+ cells should be excluded to prevent monocyte and B cell
contamination. Description and representative FACS plots of ﬁdel-
ity minus, isotype controls and mean ﬂuorescent intensity with
mean cell expression values should be included. We believe that
this will ensure a robust body of literature with ﬂow data that is
reasonably comparable between studies, strengthening our
understanding of this important cell type in chronic HCV infection
without increasing unnecessary conﬂicts within the literature.
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Fig. 1. CD56dimCD16neg NK cells, HCV treatment outcome, and the impact of
live/dead staining. (A) Pretreatment CD56dimCD16neg NK cells in 24 HCV patients
who have achieved SVR (triangles) and failed treatment (inverted triangles, mean
7.4 and 8.4%, respectively p = not signiﬁcant). (B) CD56dim NK cell proportion and
treatment outcome (mean 92.5 and 88.4%, respectively p = not signiﬁcant).
(C) CD56 and CD16 expression in an NK cell population from which dead cells
have not been excluded. (D) Alive/dead staining on CD56dimCD16neg NK cells
highlighted quadrant in (C) shown by black line. Solid grey population represents
the cells from the other 3 quadrants of CD56bright or CD16+ NK cells. (E) The
proportion of NK cells which are dead, stain positive in CD56dimCD16neg gate and
from the remaining CD56bright or CD16+ gates. Mean and SEM shown.
Reply to: ‘‘Flow cytometry makes all the difference’’
Does it? No, it doesn’t
To the Editor:
We thank Pembroke and colleagues for the comments to our
paper which, we are pleased to note, is generating interest in
the small community of liver immunologists. Contrary to our data,
they found no difference in the percentage of CD56dim/CD16neg NK
cells between patients developing a sustained virological
response (SVR) and those who failed treatment, and hypothesize
that the higher proportion of CD56dim/CD16neg NK cells at base-
line and on treatment, which we describe to be associated with
SVR in patients with chronic HCV infection, could be due to
increased proportions of dead cells in this particular NK subset.
Curiously, retrospective ﬂow cytometric analysis of their mono-
nuclear cell samples stored in liquid nitrogen revealed that the
vast majority of CD56dim/CD16neg NK cells (mean 95%) were actu-
ally composed of dead cells. In view of this unexpected ﬁnding,
Pembroke concludes that our data are not compatible with those
of others (which?), being ﬂawed by a purportedly high number of
dead cells in this speciﬁc NK-cell subset. Beside any technical con-
sideration, and even allowing for this being indeed the cause of
our ﬁndings, the ﬁrst comment that comes to one’s mind is why
would dead NK cells concentrate in SVR patients only and not in
non-responders (NR) or relapsers and why would they be
Letters to the Editor
910 Journal of Hepatology 2013 vol. 59 j 908–913
